Compare · RAL vs TMO
RAL vs TMO
Side-by-side comparison of Ralliant Corporation (RAL) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RAL and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $232.26B, about 34.0x RAL ($6.83B).
- TMO has been more active in the news (10 items in the past 4 weeks vs 9 for RAL).
- TMO has more recent analyst coverage (25 ratings vs 15 for RAL).
- Company
- Ralliant Corporation
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $6.83B
- $232.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 9
- 10
- Recent ratings
- 15
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RAL
- SVP - Chief People Officer Bick Karen M. sold $436,464 worth of shares (6,062 units at $72.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 4,922 shares, decreasing direct ownership by 26% to 31,668 units (SEC Form 4)
- SVP - Chief Technology Officer Kazmi Amir A. covered exercise/tax liability with 4,345 shares, decreasing direct ownership by 9% to 42,439 units (SEC Form 4)
- Chief Accounting Officer Osben Teo covered exercise/tax liability with 2,096 shares and was granted 14,542 shares, increasing direct ownership by 26% to 60,104 units (SEC Form 4)
- SVP - Chief Legal Officer Boatman Jonathon E. covered exercise/tax liability with 1,070 shares, decreasing direct ownership by 4% to 28,718 units (SEC Form 4)
- President and CEO Newcombe Tamara S. exercised 12,936 shares at a strike of $31.86, sold $928,675 worth of shares (12,936 units at $71.79) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,070 shares, decreasing direct ownership by 2% to 246,897 units (SEC Form 4)
- SVP - Chief Financial Officer Reynolds Neill covered exercise/tax liability with 5,674 shares, decreasing direct ownership by 9% to 55,266 units (SEC Form 4)
- SEC Form 144 filed by Ralliant Corporation
- SEC Form SCHEDULE 13G filed by Ralliant Corporation
- Ralliant Declares Regular Quarterly Dividend
- SEC Form 10-Q filed by Ralliant Corporation
Latest TMO
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 20,000 shares at a strike of $309.63 and sold $12,561,823 worth of shares (20,000 units at $628.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)